Are the Yervoy (ipilimumab) dose numbers the same across all melanoma stages?
Yes. Yervoy’s dosing is generally based on the treatment regimen (who is being treated and which schedule is being used), not on the specific “stage number” of melanoma. Stage affects whether a patient gets adjuvant therapy, neoadjuvant/adjuvant therapy, or treatment for metastatic disease, but the dose level within a given regimen is typically the same.
For melanoma, the common Yervoy dose used in major clinical regimens is 3 mg/kg given intravenously on the standard schedule (for example, as part of combination therapy with nivolumab, or as single-agent ipilimumab in certain settings). That same 3 mg/kg dose is used across the melanoma populations included in those regimens, rather than changing the dose upward or downward solely because the melanoma is stage II vs stage III vs stage IV.
Does the dosing change for stage II/III (adjuvant or neoadjuvant) versus stage IV (metastatic)?
The dose number used in the key melanoma regimens is still the same, but what does change with stage is:
- whether Yervoy is used as adjuvant/neoadjuvant therapy or for unresectable/metastatic disease, and
- whether it is given alone or with nivolumab.
So you may see different schedules or combinations depending on the stage and clinical intent, but the core “dose number” (e.g., the mg/kg level) is not typically rewritten just to match the stage.
Why might two melanoma patients with different stages still get “different looking” dosing?
Even if the mg/kg dose number is the same, schedules can differ in practice because of regimen design and clinical context, such as:
- combination with nivolumab versus ipilimumab alone
- initial induction cycles versus ongoing phases (where applicable to the regimen)
- treatment delays or dose holds due to immune-related side effects (adverse events), which can temporarily change how much the patient actually receives
When would stage-based dosing differences be more likely?
Stage alone usually doesn’t change the dose number. Differences are more likely to come from factors like:
- switching regimens (for example, adjuvant vs metastatic protocols)
- organ function and other patient-specific eligibility constraints
- management of immune-related toxicities (dose holds, discontinuation, or adjusted timing)
What dose do you mean by “dose numbers”?
If you tell me the exact Yervoy regimen you’re asking about (single-agent 3 mg/kg vs combination schedule with nivolumab, and whether it’s adjuvant/neoadjuvant or metastatic), I can help map which “dose number” applies to that specific melanoma setting.